Across TCGA pan-cancer cohorts, GYG2-AS1 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of GYG2-AS1’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where GYG2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GYG2-AS1 is over-expressed in tumor.
STAD are the cancer types where GYG2-AS1 tumor–normal differential expression is most reproducible.